What is it about?

In this review, we examine drugs repurposed for the primary factors responsible for SCI pathogenesis and to counter the associated secondary complications. We also highlight adjunctive therapy options. In addition, the chemistry and molecular processes of various repurposed drugs, including those undergoing clinical trials, are highlighted. This review is aimed mainly at medical researchers, neurologists, pharmacologists, biotech and pharmaceutical industry professionals and healthcare administrators to help them find new therapeutic strategies for spinal cord injury

Featured Image

Why is it important?

Drug repurposing in spinal cord injury (SCI) holds immense significance due to its potential to expedite the discovery of effective treatments while minimizing costs and risks associated with developing new drugs from scratch. Given the complex nature of SCI and the limited success of conventional treatments, repurposing existing drugs offers a promising avenue to identify compounds that could target multiple pathways involved in injury and repair mechanisms. This approach leverages the vast pool of already approved drugs for other conditions, accelerating the translation of research findings into clinical applications. Furthermore, repurposing allows for rapid clinical trials, as safety profiles and pharmacokinetics of repurposed drugs are already established, potentially bringing much-needed therapies to SCI patients more swiftly.

Perspectives

Drug repurposing has gained popularity as a means of creating a new use for already existing medications leading to reduced drug development costs and times; replacing an original drug to counter toxic adverse effects; reducing the cost and effort of a lengthy drug design process and finding a better approach for treatment. However, there are challenges related to adopting repurposed pharmaceuticals owing to hurdles such as cost effectiveness, the complicated clinical trial process and a lack of interest by pharmaceutical companies and researchers to participate in finding the repurposed effect of an existing drug. Drug repurposing has gained popularity as a means of creating new medications because of its many benefits, including reduced drug development costs and times. However, it comes with its own unique set of difficulties like lack of a specific target, limited knowledge of the mechanism of action, improper dose optimisation and clinical trial design. The pharmaceutical industry will need to show creativity and persistence to overcome the challenges associated with medication repurposing. While there has been much progress in the discovery of medicines for SCI, there remains an immediate requirement for innovative therapeutic pharmaceuticals that may intervene in essential pathways involved in SCI development. With the increasing understanding and enthusiasm among scientific and pharmaceutical communities around drug repurposing, the search for novel SCI treatment options is moving in the right direction.

Mr Lahanya Guha

Read the Original

This page is a summary of: Drug Repurposing for Spinal Cord Injury: Progress Towards Therapeutic Intervention for Primary Factors and Secondary Complications, Pharmaceutical Medicine, September 2023, Springer Science + Business Media,
DOI: 10.1007/s40290-023-00499-3.
You can read the full text:

Read

Resources

Contributors

The following have contributed to this page